Why the study?
Optimisation of antiplatelet therapy had not been investigated in patients with AMI after achieving complete revascularisation with an abluminal in-groove biodegradable polymer rapamycin-eluting stent.
Does short antiplatelet therapy (inhibitor monotherapy) reduce net adverse clinical and cerebral events compared to standard 12-month DAPT in patients with AMI after complete revascularisation?
Does short antiplatelet therapy (inhibitor monotherapy) reduce net adverse clinical and cerebral events compared to standard 12-month DAPT in patients with AMI after complete revascularisation?
The TARGET-FIRST trial is designed to determine if short antiplatelet therapy is non-inferior to standard 12-month DAPT in AMI patients following complete revascularization.
Short DAPT monotherapy in revascularised patients remains unproven in cohort data; leaves clinical adoption open pending RCTs.
inhibitor monotherapy (experimental arm), or 2) continued DAPT with the same regimen (control arm), up until 12 months. With a final sample size of 2,246 patients, the study is powered to evaluate the primary endpoint (non-inferiority of short antiplatelet therapy in completely revascularised patients) for net adverse clinical and cerebral events. If the primary endpoint is met, the study is powered to assess the main secondary endpoint (superiority of short DAPT in terms of major or clinically relevant non-major bleeding). TARGET-FIRST is the first randomised clinical trial to investigate the optimisation of antiplatelet therapy in patients with AMI after achieving complete revascularisation with an abluminal in-groove biodegradable polymer rapamycin-eluting stent implantation.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: